149 related articles for article (PubMed ID: 7544201)
1. Palliation of obstructive nephropathy due to malignancy.
Harrington KJ; Pandha HS; Kelly SA; Lambert HE; Jackson JE; Waxman J
Br J Urol; 1995 Jul; 76(1):101-7. PubMed ID: 7544201
[TBL] [Abstract][Full Text] [Related]
2. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases.
Ishioka J; Kageyama Y; Inoue M; Higashi Y; Kihara K
J Urol; 2008 Aug; 180(2):618-21; discussion 621. PubMed ID: 18554655
[TBL] [Abstract][Full Text] [Related]
3. The role of percutaneous nephrostomy in malignant ureteric obstruction.
Wilson JR; Urwin GH; Stower MJ
Ann R Coll Surg Engl; 2005 Jan; 87(1):21-4. PubMed ID: 15720902
[TBL] [Abstract][Full Text] [Related]
4. Factors Affecting Survival Outcome After Percutaneous Nephrostomy as Palliative Urinary Diversion in Obstructive Uropathy due to Advance Cervical Cancer Patients.
Noegroho BS; Kurniawan AP; Wijayanti Z; Mustafa A
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1211-1216. PubMed ID: 33906314
[TBL] [Abstract][Full Text] [Related]
5. Palliative percutaneous and endoscopic urinary diversion for malignant ureteral obstruction.
Gasparini M; Carroll P; Stoller M
Urology; 1991 Nov; 38(5):408-12. PubMed ID: 1719688
[TBL] [Abstract][Full Text] [Related]
6. Impact of palliative urinary diversion by percutaneous nephrostomy drainage and ureteral stenting among patients with advanced cervical cancer and obstructive uropathy: a prospective cohort.
Lapitan MC; Buckley BS
J Obstet Gynaecol Res; 2011 Aug; 37(8):1061-70. PubMed ID: 21481096
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous urinary diversion: an alternative to percutaneous nephrostomy.
Lingam K; Paterson PJ; Lingam MK; Buckley JF; Forrester A
J Urol; 1994 Jul; 152(1):70-2. PubMed ID: 8201692
[TBL] [Abstract][Full Text] [Related]
8. A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients.
Cordeiro MD; Coelho RF; Chade DC; Pessoa RR; Chaib MS; Colombo-Júnior JR; Pontes-Júnior J; Guglielmetti GB; Srougi M
BJU Int; 2016 Feb; 117(2):266-71. PubMed ID: 25327474
[TBL] [Abstract][Full Text] [Related]
9. Renal and urologic problems: management of ureteric obstruction.
Liberman D; McCormack M
Curr Opin Support Palliat Care; 2012 Sep; 6(3):316-21. PubMed ID: 22643703
[TBL] [Abstract][Full Text] [Related]
10. Use of nephrostomy tubes in ureteric obstruction from incurable malignancy.
Little B; Ho KJ; Gawley S; Young M
Int J Clin Pract; 2003 Apr; 57(3):180-1. PubMed ID: 12723719
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous nephrostomy in gynecologic oncology patients.
Soper JT; Blaszczyk TM; Oke E; Clarke-Pearson D; Creasman WT
Am J Obstet Gynecol; 1988 May; 158(5):1126-31. PubMed ID: 2453117
[TBL] [Abstract][Full Text] [Related]
12. The role of percutaneous nephrostomy in malignant urinary tract obstruction.
Watkinson AF; A'Hern RP; Jones A; King DM; Moskovic EC
Clin Radiol; 1993 Jan; 47(1):32-5. PubMed ID: 8428414
[TBL] [Abstract][Full Text] [Related]
13. Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes.
Kouba E; Wallen EM; Pruthi RS
J Urol; 2008 Aug; 180(2):444-50. PubMed ID: 18550089
[TBL] [Abstract][Full Text] [Related]
14. Outcome of palliative urinary diversion in the treatment of advanced malignancies.
Shekarriz B; Shekarriz H; Upadhyay J; Banerjee M; Becker H; Pontes JE; Wood DP
Cancer; 1999 Feb; 85(4):998-1003. PubMed ID: 10091780
[TBL] [Abstract][Full Text] [Related]
15. Nonoperative urinary diversion for malignant ureteral obstruction.
Zadra JA; Jewett MA; Keresteci AG; Rankin JT; St Louis E; Grey RR; Pereira JJ
Cancer; 1987 Sep; 60(6):1353-7. PubMed ID: 3621117
[TBL] [Abstract][Full Text] [Related]
16. Obstructive uropathy in gynecologic malignancy. Detrimental effect of intraureteral stent placement and value of percutaneous nephrostomy.
Hyppolite JC; Daniels ID; Friedman EA
ASAIO J; 1995; 41(3):M318-23. PubMed ID: 8573816
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic malignancy: have we got the balance right?
Misra S; Coker C; Richenberg J
Int Urol Nephrol; 2013 Jun; 45(3):627-32. PubMed ID: 23666587
[TBL] [Abstract][Full Text] [Related]
18. Management of extrinsic malignant ureteral obstruction with urinary diversion.
Kanou T; Fujiyama C; Nishimura K; Tokuda Y; Uozumi J; Masaki Z
Int J Urol; 2007 Aug; 14(8):689-92. PubMed ID: 17681056
[TBL] [Abstract][Full Text] [Related]
19. Clinical Factors Associated With a Short Survival Time After Percutaneous Nephrostomy for Ureteric Obstruction in Cancer Patients: An Updated Model.
Alawneh A; Tuqan W; Innabi A; Al-Nimer Y; Azzouqah O; Rimawi D; Taqash A; Elkhatib M; Klepstad P
J Pain Symptom Manage; 2016 Feb; 51(2):255-61. PubMed ID: 26497918
[TBL] [Abstract][Full Text] [Related]
20. Maintaining quality of life after palliative diversion for malignant ureteral obstruction.
Markowitz DM; Wong KT; Laffey KJ; Bixon R; Nagler HM; Martin EC
Urol Radiol; 1989; 11(3):129-32. PubMed ID: 2480679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
